Video
Dr. Kulke on Emerging Cabozantinib Data for NETs
Author(s):
Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).
Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).
There are several new treatments that are focused on tumor control for patients with NETs, says Kulke. There was a phase II study of cabozantinib, which targets the VEGF receptor and c-MET.
Phase II studies show encouraging results, explains Kulke. Based on those results, cabozantinib is going to be taken forward into a large randomized study that is designed as a registrational study.
Partial responses were observed in 15% of each cohort treated with cabozantinib, and stable disease was the best response in about two-thirds of patients. Median progression-free survival exceeded 20 months in patients with pancreatic NETs and was >30 months in the carcinoid tumor cohort.
